Sofinnova Venture Partners X, L.P.

Filings by Sofinnova Venture Partners X, L.P. span 3 companies, the busiest being Vera Therapeutics, Inc., CinCor Pharma, Inc. and Jade Biosciences, Inc. In total, 6 filings cover trades dated from 18 May 2021 to 6 February 2023.

Every open-market trade on record is a purchase: 3 purchases worth €19.9M, and no sale. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. In 2023 alone, the filings show 1 purchase and no sales.

The median purchase comes to €3.5M. Clusters matter here: 2 out of 3 purchases overlapped with buying by a colleague within 30 days. Purchases made close together by different insiders form what is called a cluster.

On 8 February 2023 came the latest disclosure, an open-market purchase for €1.9M in Vera Therapeutics, Inc. Filings reach the SEC (Form 4) feed a median of 4 days after the trade. US insiders must file a Form 4 within two business days of a trade. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.